Why is this study being conducted?
This research study is testing a potential new treatment for Dupuytren’s Contracture called CNT201. Dupuytren’s contracture is a condition that causes one or more fingers to bend toward the palm of the hand. Knots of tissue form under the skin. They eventually create a thick cord that can pull the fingers into a bent position and the affected fingers cannot straighten completely. The main purpose of this research is to look at the safety and tolerability of the investigational study drug, CNT201, and whether it works when given to patients with Dupuytren’s contracture.
Who is eligible to participate in this study?
You may be eligible if you:
- Are between 18 and 75 years of age
- Have a diagnosis of primary Dupuytren’s Contracture
Applicants who express interest in participating in this study will be reviewed and contacted as other requirement criteria must also be met.
What happens during the study?
Trial duration will be about two months and you will have about eight trial visits.
Trial site visits will occur at the Griffith University Clinical Trial Unit on the Gold Coast.
In Part 1 of the study participants will receive a single injection of CNT201 at one of four dose levels.
In Part 2 of the study participants will receive up to three injections of CNT201 or placebo.
Volunteer to participate
Participation in this study is completely voluntary, and participants can decide to withdraw at any time.
Eligible participants will be reimbursed for their time and travel associated with each study visit.
Contact Taryn Houghton
To learn more about this clinical trial, please contact:
Taryn Houghton, Clinical Trial Coordinator.
07 5678 0368 clinicaltrialunit@griffith.edu.au
This study has been approved by Bellberry Human Research Ethics Committee #2024-04-447 and GU HREC #2024/657.
Can't see a trial for you?
Join our volunteer database to be contacted about new clinical trials